Press Releases

AIRNA Appoints Matthew Hawryluk as Chief Business Officer

Cambridge, MA, USA and Tübingen, Germany, January 30, 2025 – AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a […]

$

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

Financing led by Forbion and includes participation from ARCH Venture Partners and a broad syndicate of world-class investors New funds will advance product candidate for the treatment of alpha-1 antitrypsin deficiency (AATD) into clinical trials Josh Brumm, General Partner at Forbion, to join AIRNA Board of Directors Cambridge, MA, USA and Tübingen, Germany, July 31, 2024 […]

$

Publications

Precision RNA base editing with engineered and endogenous effectors

Laura S Pfeiffer, Thorsten Stafforst. Nat Biotechnol. 2023 Sep 21. doi: 10.1038/s41587-023-01927-0.

$

Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, Wettengel J, Li JB, Stafforst T. Nat Biotechnol 2019, 37:133-138, doi: 10.1038/s41587-019-0013-6, PMID: 30692694.

$